A Phase 3 Study of Xaluritamig Versus Cabazitaxel or Second Androgen Receptor-Directed Therapy for People With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

In the U.S.

Full Title

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy (WCG)

Purpose

Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).

Researchers are comparing xaluritamig, a new immunotherapy, with standard treatment in people with CRPC who previously received chemotherapy. If you take part in this study, you will be randomly assigned to get one of these treatments:

Xaluritamig, given intravenously (by vein)
Cabazitaxel (a type of chemotherapy, also given intravenously)
Second androgen receptor-directed therapy (ARDT), such as abiraterone acetate or enzalutamide. Both treatments block the effects of testosterone. They are taken orally (by mouth).